Lurasidone drug-drug interaction studies: A comprehensive review

Drug Metabolism and Drug Interactions

Volumn 29, Issue 3, 2014, Pages 191-202

  Chiu, Yu Yuan ^a   Ereshefsky, Larry ^b   Preskorn, Sheldon H ^c   Poola, Nagaraju ^a   Loebel, Antony ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b PAREXEL INTERNATIONAL   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

Atypical antipsychotic; Drug interactions; Lurasidone; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 INDUCER; CYTOCHROME P450 INHIBITOR; DIGOXIN; DILTIAZEM; DRUG METABOLITE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; KETOCONAZOLE; LITHIUM; LURASIDONE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; NORELGESTROMIN; RIFAMPICIN; VALPROIC ACID; CYTOCHROME P450 3A; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A INHIBITOR; ISOINDOLE DERIVATIVE; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT; THIAZOLE DERIVATIVE;

AKATHISIA; AREA UNDER THE CURVE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; DRUG BLOOD LEVEL; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; MUSCLE RIGIDITY; NAUSEA; PARKINSONISM; PATHOLOGICAL REFLEX; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOMOTOR RETARDATION; REPEATED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TREMOR; TRISMUS; VOMITING; DRUG COMBINATION; DRUG INTERACTION;

ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CLINICAL TRIALS, PHASE I AS TOPIC; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INDUCERS; CYTOCHROME P-450 CYP3A INHIBITORS; DILTIAZEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; ISOINDOLES; KETOCONAZOLE; LITHIUM COMPOUNDS; RIFAMPIN; THIAZOLES;

EID: 84925459877     PISSN: 07925077     EISSN: 21910162     Source Type: Journal    
DOI: 10.1515/dmdi-2014-0005     Document Type: Review

References (33)

1. 1A receptor activity. J Pharmacol Exp Ther 2010;334:171-81.
2. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65:189-210.
3. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18:1715-26.
4. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
5. Latuda® (lurasidone hydrochloride) tablets, for oral use [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc., 2013.
6. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77.
7. Wong FA, Edom RW, Duda M, Tischio JP, Huang M, Juzwin S, et al. Determination of norgestimate and its metabolites in human serum using high-performance liquid chromatography with tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 1999;734:247-55.
8. Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG, Siiteri PK. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception 2003;67:93-9.
9. Ortho Tri-Cyclen® tablets [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2010.
10. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171:169-77.
11. Lurasidone HCI - a 6-week phase 3 study of patients with bipolar I depression (PREVAIL3), NCT01284517. ClinicalTrials.gov. 2012 Aug 29 [online]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01284517?term?=?01284517&rank?=?1. Accessed 2014 Feb 24.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association, 2000.
13. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999;115:12-8.
14. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995;29:172-91.
15. Horn JR, Hansten PD. Get to know an enzyme: CYP3A4. Pharmacy Times. September 1, 2008;1-3.
16. Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2014; 10:721-46.
17. Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs 2013;27:1021-48.
18. English BA, Dortch M, Ereshefsky L, Jhee S. Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep 2012;14:376-90.
19. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57:Suppl 11:12-25.
20. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003;17:517-38.
21. Mahatthanatrakul W, Sriwiriyajan S, Ridtitid W, Boonleang J, Wongnawa M, Rujimamahasan N, et al. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. J Clin Pharm Ther 2012;37:221-5.
22. Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunbhanich M. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J Clin Pharm Ther 2007;32:161-7.
23. Kim KA, Park PW, Liu KH, Kim KB, Lee HJ, Shin JG, et al. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol 2008;48:66-72.
24. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22.
25. Moons T, de Roo M, Claes S, Dom G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 2011;12:1193-211.
26. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, De Vane CL. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 2004;29:551-7.
27. Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol 2005;20:493-500.
28. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 2003;43:1274-82.
29. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18:472-84.
30. Sabers A. Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure 2008;17:141-4.
31. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev 2007;3:CD003834.
32. Eskalith® (lithium carbonate) capsules and controlled-release tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2003.
33. Bergemann N, Abu-Tair F, Kress KR, Parzer P, Kopitz J. Increase in plasma concentration of amisulpride after addition of concomitant lithium. J Clin Psychopharmacol 2007;27:546-9.